Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients

Turk M., YILMAZ İ., Bahcecioglu S. N.

ALLERGOLOGY INTERNATIONAL, cilt.67, sa.1, ss.85-89, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 67 Sayı: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.alit.2017.05.003
  • Dergi Adı: ALLERGOLOGY INTERNATIONAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.85-89
  • Anahtar Kelimeler: Anti-IgE antibody, Management, Omalizumab, Retreatment, Urticaria, CHRONIC IDIOPATHIC URTICARIA, CLINICAL-PRACTICE, MANAGEMENT, DIAGNOSIS, UPDATE, GUIDELINE, EFFICACY, THERAPY
  • Erciyes Üniversitesi Adresli: Evet

Özet

Background: Previous data have shown the high efficacy of omalizumab in chronic spontaneous urticaria (CSU). However, factors that may be effective on the response to therapy, relapse rates after drug discontinuation, and efficacy of retreatment remain unclear. This study aimed to determine the efficacy of omalizumab in CSU refractory to conventional therapy, to identify possible factors affecting treatment response and relapse, and also to evaluate the efficacy of retreatment on relapsed disease.